SCHEMBL3884093

SCHEMBL3884093

O=C(Cl)C(=O)c1c(-c2cccnc2Cl)cc2ccccn12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.46
L3MBTL1 Q9Y468 6/20 0.41
THRB P10828 1/20 0.41
MAPT P10636 4/20 0.39
HTT P42858 2/20 0.39
KDM4E B2RXH2 4/20 0.39
ALDH1A1 P00352 4/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
KMT2A Q03164 3/20 0.37
RAB9A P51151 3/20 0.37
MEN1 O00255 2/20 0.37
MAPK1 P28482 1/20 0.37
ATM Q13315 1/20 0.36
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1645071 0.86 SMN1; SMN2 (0.48) SMN1; SMN2L3MBTL1THRBMAPTHTT
SCHEMBL1646968 0.83 SMN1; SMN2 (0.48) SMN1; SMN2L3MBTL1THRBMAPTHTT
SCHEMBL3883352 0.82 BAZ2B (0.50) SMN1; SMN2L3MBTL1THRBMAPTHTT
SCHEMBL3886862 0.79 SMN1; SMN2 (0.50) SMN1; SMN2L3MBTL1THRBMAPTHTT
SCHEMBL3886464 0.79 SMN1; SMN2 (0.56) SMN1; SMN2L3MBTL1THRBMAPTHTT
SCHEMBL3889228 0.78 SMN1; SMN2 (0.55) SMN1; SMN2L3MBTL1THRBMAPTHTT
SCHEMBL1645731 0.77 SMN1; SMN2 (0.68) SMN1; SMN2L3MBTL1THRBMAPTHTT
SCHEMBL3886971 0.76 SMN1; SMN2 (0.47) SMN1; SMN2L3MBTL1THRBMAPTHTT
SCHEMBL8002223 0.75 SMN1; SMN2 (0.49) SMN1; SMN2L3MBTL1THRBMAPTHTT
SCHEMBL3885387 0.74 SMN1; SMN2 (0.54) SMN1; SMN2L3MBTL1THRBMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8486962-B2 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus F2G LTD. (GB) 2013-07-16 US disclosed
EP-1888063-B1 ANTIFUNGAL AGENTS F2G LTD (GB) 2009-01-14 EP disclosed
US-20080161302-A1 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus F2G LTD. (GB) 2008-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161302-A1 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus NAT1, CYP1A2, CYP51A1 SMN1; SMN2 3501/4885L3MBTL1 3386/4885THRB 2955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.